Forma Therapeutics, Inc.
Clinical trials sponsored by Forma Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing therapies for rare diseases and cancer, acquired by Novo Nordisk.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could shield kids with sickle cell from stroke Results expected Aug 2027 (estimated) May already have reported ↗
-
New drug targets genetic weakness in Hard-to-Treat blood cancers
Disease control CompletedThis study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is …
Phase 1/2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could cut blood transfusions for blood disorders
Disease control CompletedThis Phase 2 study tested an experimental drug called etavopivat in 53 people with thalassemia or sickle cell disease. The goal was to see if the pill could safely reduce the number of red blood cell transfusions needed and raise hemoglobin levels. Participants took 400 mg of eta…
Phase 2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC